AU776647B2 - Composition and method for treatment of otitis media - Google Patents
Composition and method for treatment of otitis media Download PDFInfo
- Publication number
- AU776647B2 AU776647B2 AU70798/00A AU7079800A AU776647B2 AU 776647 B2 AU776647 B2 AU 776647B2 AU 70798/00 A AU70798/00 A AU 70798/00A AU 7079800 A AU7079800 A AU 7079800A AU 776647 B2 AU776647 B2 AU 776647B2
- Authority
- AU
- Australia
- Prior art keywords
- phospholipid
- mixture
- mixtures
- cholesteryl
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 154
- 239000000203 mixture Substances 0.000 title claims description 107
- 206010033078 Otitis media Diseases 0.000 title claims description 31
- 150000002632 lipids Chemical class 0.000 claims description 98
- 210000002388 eustachian tube Anatomy 0.000 claims description 82
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 73
- 150000003904 phospholipids Chemical class 0.000 claims description 70
- 239000003380 propellant Substances 0.000 claims description 63
- 210000000959 ear middle Anatomy 0.000 claims description 59
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 230000008569 process Effects 0.000 claims description 53
- 230000007480 spreading Effects 0.000 claims description 50
- 238000003892 spreading Methods 0.000 claims description 50
- 239000013078 crystal Substances 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 40
- 239000013543 active substance Substances 0.000 claims description 39
- 239000004094 surface-active agent Substances 0.000 claims description 39
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 28
- -1 pneumogalactan Chemical compound 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 21
- 229960003276 erythromycin Drugs 0.000 claims description 17
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 17
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 14
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical group CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 14
- 229960002537 betamethasone Drugs 0.000 claims description 13
- 229960001802 phenylephrine Drugs 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 229940088710 antibiotic agent Drugs 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 9
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 claims description 8
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 8
- 229960003022 amoxicillin Drugs 0.000 claims description 8
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 8
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical group C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 claims description 7
- 239000003580 lung surfactant Substances 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims description 6
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 claims description 6
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 claims description 6
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 claims description 6
- 239000000850 decongestant Substances 0.000 claims description 6
- 239000008121 dextrose Substances 0.000 claims description 6
- 229930182830 galactose Natural products 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 3
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 3
- 229960004311 betamethasone valerate Drugs 0.000 claims description 3
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 3
- NHKOTKKHHYKARN-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[(1r)-1-hydroxy-2-(methylamino)ethyl]phenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=CC(O)=C1 NHKOTKKHHYKARN-NDAAPVSOSA-N 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 229960003680 phenylephrine bitartrate Drugs 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 12
- 210000000981 epithelium Anatomy 0.000 claims 4
- 229960004099 azithromycin Drugs 0.000 claims 2
- 229940038649 clavulanate potassium Drugs 0.000 claims 2
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims 2
- 239000013256 coordination polymer Substances 0.000 description 43
- 229940079593 drug Drugs 0.000 description 17
- 239000012530 fluid Substances 0.000 description 16
- 208000005923 otitis media with effusion Diseases 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 210000001989 nasopharynx Anatomy 0.000 description 9
- 210000003454 tympanic membrane Anatomy 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000003484 anatomy Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 5
- 229940029284 trichlorofluoromethane Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 208000022760 infectious otitis media Diseases 0.000 description 4
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229940098164 augmentin Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000015227 regulation of liquid surface tension Effects 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699684 Meriones unguiculatus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000006435 acute transudative otitis media Diseases 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000002430 laser surgery Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000002578 otoscopy Methods 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229910003873 O—P—O Inorganic materials 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/450,884 US6156294A (en) | 1999-11-28 | 1999-11-28 | Composition and method for treatment of otitis media |
| US09/450884 | 1999-11-28 | ||
| PCT/US2000/023540 WO2001037806A1 (en) | 1999-11-28 | 2000-08-28 | Composition and method for treatment of otitis media |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7079800A AU7079800A (en) | 2001-06-04 |
| AU776647B2 true AU776647B2 (en) | 2004-09-16 |
Family
ID=23789905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU70798/00A Ceased AU776647B2 (en) | 1999-11-28 | 2000-08-28 | Composition and method for treatment of otitis media |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6156294A (https=) |
| EP (1) | EP1233753B1 (https=) |
| JP (1) | JP2003514842A (https=) |
| AU (1) | AU776647B2 (https=) |
| CA (1) | CA2392367C (https=) |
| DK (1) | DK1233753T3 (https=) |
| ES (1) | ES2663082T3 (https=) |
| MX (1) | MXPA02005258A (https=) |
| WO (1) | WO2001037806A1 (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645467B2 (en) * | 1999-11-28 | 2003-11-11 | Scientific Development And Research, Inc. | Composition and method for decreasing upper respiratory airway resistance |
| US7064132B2 (en) * | 1999-11-28 | 2006-06-20 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis external |
| US6676930B2 (en) * | 1999-11-28 | 2004-01-13 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| US6599441B1 (en) * | 2000-07-18 | 2003-07-29 | Emerald Biostructures, Inc. | Crystallization solutions |
| FR2812545B1 (fr) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
| DE10105592A1 (de) | 2001-02-06 | 2002-08-08 | Achim Goepferich | Platzhalter zur Arzneistofffreigabe in der Stirnhöhle |
| US20040022740A1 (en) * | 2001-07-10 | 2004-02-05 | Baker William R. | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| US8317816B2 (en) | 2002-09-30 | 2012-11-27 | Acclarent, Inc. | Balloon catheters and methods for treating paranasal sinuses |
| WO2004052236A2 (en) * | 2002-12-06 | 2004-06-24 | Arriva Pharmaceuticals, Inc. | Methods and compositions for treatment of otitis media |
| DK1638524T3 (da) * | 2003-07-02 | 2010-12-20 | Swimseal Internat Pty Ltd | Sammensætning og fremgangsmåde til behandling af vandrelaterede øreproblemer |
| US8940321B2 (en) | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| WO2005055921A2 (en) * | 2003-12-12 | 2005-06-23 | Eran Eilat | Compositions for treatment of ear disorders and methods of use thereof |
| WO2005058879A1 (ja) * | 2003-12-17 | 2005-06-30 | Kansai Medical University | 滲出性中耳炎の予防および／または治療剤 |
| WO2005104691A2 (en) * | 2004-04-15 | 2005-11-10 | Graco Minnesota Inc. | Automatic dose size selection for multi-component fluid proportioners |
| US20070208252A1 (en) | 2004-04-21 | 2007-09-06 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
| US7462175B2 (en) | 2004-04-21 | 2008-12-09 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
| US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
| US20060004323A1 (en) | 2004-04-21 | 2006-01-05 | Exploramed Nc1, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
| US7410480B2 (en) | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
| US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
| US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
| US7559925B2 (en) | 2006-09-15 | 2009-07-14 | Acclarent Inc. | Methods and devices for facilitating visualization in a surgical environment |
| US20190314620A1 (en) | 2004-04-21 | 2019-10-17 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
| US20060063973A1 (en) | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
| US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| US8146400B2 (en) | 2004-04-21 | 2012-04-03 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
| US20070167682A1 (en) | 2004-04-21 | 2007-07-19 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
| US8747389B2 (en) | 2004-04-21 | 2014-06-10 | Acclarent, Inc. | Systems for treating disorders of the ear, nose and throat |
| US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
| US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
| US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
| US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
| US8702626B1 (en) | 2004-04-21 | 2014-04-22 | Acclarent, Inc. | Guidewires for performing image guided procedures |
| US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
| US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
| CA2567334A1 (en) * | 2004-05-20 | 2005-12-08 | Discovery Laboratories, Inc. | Methods , systems and devices for noninvasive pulmonary delivery |
| US8337481B2 (en) | 2005-01-25 | 2012-12-25 | Patrick Slater | Method for treating otitis externa |
| US7981104B2 (en) * | 2005-01-25 | 2011-07-19 | Patrick Slater | Method for treating otitis externa |
| EP1858506A2 (en) * | 2005-03-10 | 2007-11-28 | 3M Innovative Properties Company | Methods of treating ear infections |
| US8028697B2 (en) | 2005-04-28 | 2011-10-04 | Trudell Medical International | Ventilator circuit and method for the use thereof |
| US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
| US8114113B2 (en) | 2005-09-23 | 2012-02-14 | Acclarent, Inc. | Multi-conduit balloon catheter |
| US20070173463A1 (en) * | 2006-01-20 | 2007-07-26 | Brechtelsbauer Paul B | Method and composition for treating otitis media |
| AU2007221150B2 (en) * | 2006-02-27 | 2012-09-20 | Ahm Technologies, Inc. | Eustachian tube device and method |
| US7959943B2 (en) | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
| US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
| US7976873B2 (en) | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
| US7993675B2 (en) | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
| US8190389B2 (en) | 2006-05-17 | 2012-05-29 | Acclarent, Inc. | Adapter for attaching electromagnetic image guidance components to a medical device |
| US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
| US8439687B1 (en) | 2006-12-29 | 2013-05-14 | Acclarent, Inc. | Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices |
| US8088095B2 (en) | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
| WO2008124787A2 (en) | 2007-04-09 | 2008-10-16 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
| US8118757B2 (en) | 2007-04-30 | 2012-02-21 | Acclarent, Inc. | Methods and devices for ostium measurement |
| US8485199B2 (en) | 2007-05-08 | 2013-07-16 | Acclarent, Inc. | Methods and devices for protecting nasal turbinate during surgery |
| US20100198191A1 (en) | 2007-12-20 | 2010-08-05 | Acclarent, Inc. | Method and system for treating target tissue within the eustachian tube |
| US10206821B2 (en) | 2007-12-20 | 2019-02-19 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
| US8182432B2 (en) | 2008-03-10 | 2012-05-22 | Acclarent, Inc. | Corewire design and construction for medical devices |
| HUE028653T2 (en) | 2008-03-17 | 2016-12-28 | Discovery Lab Inc | Respiratory circuit adapter and direct aerosol delivery system |
| KR101621726B1 (ko) * | 2008-05-27 | 2016-05-17 | 더 유니버시티 오브 멜버른 | 유스타키오관 기능장애 치료용 국소 약학적 조성물 |
| CA2727432C (en) | 2008-06-12 | 2016-10-11 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
| KR101653180B1 (ko) | 2008-07-30 | 2016-09-01 | 아클라런트, 인코포레이션 | 부비 개구 탐지기 장치 및 방법 |
| RU2506056C2 (ru) | 2008-09-18 | 2014-02-10 | Аккларент, Инк. | Способы и аппарат для лечения заболеваний уха, горла, носа |
| EP2346324A4 (en) | 2008-10-06 | 2012-10-10 | Microbial Defense Systems Llc | ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING |
| US8596265B2 (en) | 2008-10-22 | 2013-12-03 | Trudell Medical International | Modular aerosol delivery system |
| US20100241155A1 (en) | 2009-03-20 | 2010-09-23 | Acclarent, Inc. | Guide system with suction |
| US7978742B1 (en) | 2010-03-24 | 2011-07-12 | Corning Incorporated | Methods for operating diode lasers |
| US8435290B2 (en) | 2009-03-31 | 2013-05-07 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
| US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
| US10653133B2 (en) | 2011-05-10 | 2020-05-19 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
| US8758836B2 (en) * | 2011-09-09 | 2014-06-24 | Nina S. YOSHPE | Method and formulation for treating dry ear inflammation with cortisone |
| CN103796573A (zh) | 2011-09-15 | 2014-05-14 | 优瑟夫·雅阿科比 | 一种治疗耳病的系统和方法 |
| US9629684B2 (en) | 2013-03-15 | 2017-04-25 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
| US9433437B2 (en) | 2013-03-15 | 2016-09-06 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
| US9895311B2 (en) * | 2014-09-25 | 2018-02-20 | Pharmiva Ab | Foam-forming compositions and methods for delivering an active to a body cavity |
| CN107847713A (zh) | 2015-03-31 | 2018-03-27 | 阿克拉伦特公司 | 具有通气路径的咽鼓管扩张球囊 |
| MX2018006575A (es) * | 2015-11-30 | 2018-12-06 | Novus Therapeutics Inc | Composiciones y metodos para profilaxis otologica y tratamiento. |
| US11795192B2 (en) | 2017-03-10 | 2023-10-24 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
| CA3063208A1 (en) | 2017-05-23 | 2018-11-29 | Pharmiva Ab | Foam-forming compositions for delivering an active to a body cavity |
| FI3638251T3 (fi) | 2017-06-12 | 2024-04-29 | Lakewood Amedex Inc | Bisfosfosiinin geeliformulaatioita ja niiden käyttötapoja |
| US11331269B2 (en) * | 2018-09-06 | 2022-05-17 | Massachusetts Institute Of Technology | Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment |
| SG11202103180QA (en) | 2018-10-17 | 2021-05-28 | Lakewood Amedex Inc | Methods and compositions for treating oral mucositis |
| EP3914323A4 (en) * | 2019-01-23 | 2022-10-05 | Alrich Partners, Inc. | METHOD FOR IMPROVING EUSTACHE POLE PERMEABILITY AND TREATMENT OF OTITIS MEDIA |
| JP2024522372A (ja) * | 2021-06-11 | 2024-06-18 | アンク、ライフ、サイエンシズ、リミテッド | 有効薬剤の組合せの局所送達のための安定性が向上した脂質結晶性組成物 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141674A (en) * | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| JPH0753661B2 (ja) * | 1984-03-08 | 1995-06-07 | フアレス フアーマスーチカル リサーチ エヌブイ | プロ―リポソーム組成物及びリポソームの水性分散物を作る方法 |
| GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| DE3686025T2 (de) * | 1985-05-22 | 1993-01-07 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| US4826821A (en) | 1985-06-26 | 1989-05-02 | The Regents Of The University Of California | Lung surfactant compositions |
| FR2586587B1 (fr) | 1985-08-30 | 1987-10-23 | Adir | Nouveaux surfactants artificiels, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| SE462894B (sv) * | 1985-10-28 | 1990-09-17 | Biogram Ab | Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning |
| US5013720A (en) | 1986-05-06 | 1991-05-07 | Abbott Laboratories | SAP-6-Val proteins and methods |
| SE8603812D0 (sv) | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
| CA1338736C (fr) * | 1986-12-05 | 1996-11-26 | Roger Baurain | Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation |
| IT1203873B (it) | 1987-04-08 | 1989-02-23 | Chiesi Farma Spa | Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e |
| JP2656944B2 (ja) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
| US5260273A (en) | 1988-01-06 | 1993-11-09 | The Scripps Research Institute | Pulmonary surfactant protein and related polypeptide |
| JPH01258620A (ja) * | 1988-04-08 | 1989-10-16 | Dai Ichi Seiyaku Co Ltd | 耳疾患用局所製剤 |
| MX9203504A (es) | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
| JPH01313423A (ja) * | 1988-06-03 | 1989-12-18 | Biogal Gyogyszergyar | 耳炎用点耳薬の新規製薬組成物 |
| US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| US5134129A (en) | 1989-03-15 | 1992-07-28 | Board Of Regents, The University Of Texas System | Methods employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
| US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| US5238920A (en) | 1989-08-22 | 1993-08-24 | Abbott Laboratories | Pulmonary surfactant protein fragments |
| US5888505A (en) | 1991-02-21 | 1999-03-30 | Eoe, Inc. | Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system |
| CA2108782C (en) * | 1991-04-29 | 2002-05-07 | Joseph R. Di Bartolomeo | Composition and method for treatment of patulous eustachian tube syndrome and atrophic rhinitis |
| ZA926834B (en) | 1991-09-09 | 1993-03-15 | American Cyanamid Co | Antibiotic LL-E19020 Gamma. |
| GB9120005D0 (en) | 1991-09-19 | 1991-11-06 | Wellcome Found | Method of administering phospholipid dispersions |
| ES2079994B1 (es) | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
| AR002009A1 (es) | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
| CA2213638C (en) | 1995-02-24 | 2004-05-04 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| AU5417796A (en) | 1995-03-07 | 1996-09-23 | University Of Pittsburgh | A dry powder formulation for gene therapy |
| DZ2028A1 (fr) * | 1995-05-03 | 2002-10-23 | Smithkline Beecham Plc | Médicaments destinés au traitement d'infections bactériennes en pédiatrie. |
| US5843930A (en) | 1995-06-06 | 1998-12-01 | Bayer Corporation | Method of treating otitis with ciprofloxacin-hydrocortisone suspension |
| DE69620136T2 (de) | 1995-06-06 | 2002-08-01 | Bayer Ag | Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen |
| US6129934A (en) | 1995-06-07 | 2000-10-10 | Ony, Inc. | Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction |
| WO1997029738A1 (en) * | 1996-02-16 | 1997-08-21 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating eustachian tube dysfunction by inhalation |
| US6423694B1 (en) * | 1996-02-21 | 2002-07-23 | Inspire Pharmaceuticals, Inc. | Method of treating otitis media with uridine triphosphates and related compounds |
| WO1997035882A1 (en) | 1996-03-27 | 1997-10-02 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
| USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5958378A (en) | 1996-07-03 | 1999-09-28 | Research Development Foundation | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| US5954682A (en) | 1996-09-25 | 1999-09-21 | Advanced Medical Instruments | Therapeutic applicator apparatus and method |
| KR20000048812A (ko) * | 1996-10-01 | 2000-07-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 병원성 유기체에 의한 비인두 전이증식 관련 세균 감염 치료용약제를 제조하기 위한 뮤피로신의 용도 |
| US6040463A (en) | 1996-10-07 | 2000-03-21 | Merck & Co., Inc. | Sordarin derivatives |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| EP1005327A1 (en) | 1997-07-02 | 2000-06-07 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
| US5925334A (en) | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| ES2191355T3 (es) | 1997-12-24 | 2003-09-01 | Britannia Pharmaceuticals Ltd | Uso de un tensioactivo para la preparacion de un medicamento para el tratamiento de trastornos del oido medio. |
| GB9807298D0 (en) * | 1998-04-03 | 1998-06-03 | Britannia Pharmaceuticals Ltd | Medicament |
| US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
-
1999
- 1999-11-28 US US09/450,884 patent/US6156294A/en not_active Expired - Lifetime
-
2000
- 2000-08-16 US US09/639,730 patent/US6521213B1/en not_active Expired - Lifetime
- 2000-08-16 US US09/639,739 patent/US6572841B1/en not_active Expired - Lifetime
- 2000-08-16 US US09/639,682 patent/US6616913B1/en not_active Expired - Lifetime
- 2000-08-28 JP JP2001539421A patent/JP2003514842A/ja active Pending
- 2000-08-28 ES ES00959479.7T patent/ES2663082T3/es not_active Expired - Lifetime
- 2000-08-28 AU AU70798/00A patent/AU776647B2/en not_active Ceased
- 2000-08-28 CA CA002392367A patent/CA2392367C/en not_active Expired - Lifetime
- 2000-08-28 DK DK00959479.7T patent/DK1233753T3/en active
- 2000-08-28 EP EP00959479.7A patent/EP1233753B1/en not_active Expired - Lifetime
- 2000-08-28 MX MXPA02005258A patent/MXPA02005258A/es active IP Right Grant
- 2000-08-28 WO PCT/US2000/023540 patent/WO2001037806A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| SEE REFERENCES OF WO 2001/037806 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US6156294A (en) | 2000-12-05 |
| AU7079800A (en) | 2001-06-04 |
| WO2001037806A1 (en) | 2001-05-31 |
| US6572841B1 (en) | 2003-06-03 |
| US6616913B1 (en) | 2003-09-09 |
| EP1233753A1 (en) | 2002-08-28 |
| DK1233753T3 (en) | 2018-05-22 |
| MXPA02005258A (es) | 2004-04-21 |
| CA2392367A1 (en) | 2001-05-31 |
| US6521213B1 (en) | 2003-02-18 |
| EP1233753B1 (en) | 2018-02-14 |
| EP1233753A4 (en) | 2009-09-23 |
| ES2663082T3 (es) | 2018-04-11 |
| CA2392367C (en) | 2009-08-04 |
| JP2003514842A (ja) | 2003-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU776647B2 (en) | Composition and method for treatment of otitis media | |
| US6676930B2 (en) | Composition and method for treatment of otitis media | |
| US5306483A (en) | Phospholipid delivery system | |
| JP6941224B2 (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| CA2335900C (en) | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery | |
| Khan et al. | Liposome-based carrier systems and devices used for pulmonary drug delivery | |
| RU2421209C2 (ru) | Фармацевтические композиции, содержащие циклоспорин | |
| KR20010041623A (ko) | 흡입 투여용 지방 유제 | |
| RS53329B (sr) | Postupak i smeša za lečenje inflamatornih poremećaja | |
| JP2005511648A5 (https=) | ||
| WO2007126865A2 (en) | Leukotriene antagonists via nasal drug delivery | |
| EP1460967B1 (en) | Composition and method for treatment of otitis externa | |
| US6645467B2 (en) | Composition and method for decreasing upper respiratory airway resistance | |
| US8466134B1 (en) | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery | |
| WO2002094283A2 (en) | Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs | |
| WO2003061668A1 (en) | Use of pulmonary surfactant for the prevention of infectious diseases | |
| MX2008007291A (en) | Pharmaceutical compositions comprising cyclosporin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |